Journal Article

The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation

M. A. Wood, G. N. Kay and K. A. Ellenbogen

in EP Europace

Published on behalf of European Heart Rhythm Association of the European Society of Cardiology (ESC)

Volume 1, issue 1, pages 22-25
Published in print January 1999 | ISSN: 1099-5129
Published online January 1999 | e-ISSN: 1532-2092 | DOI:
The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation

Show Summary Details


The Ablate and Pace Trial (APT) was a prospective registry study of clinical outcomes and survival following ablation and pacing therapy for medically refractory atrial fibril-lation. One hundred and fifty-six patients were enrolled at 16 centres in North America. The mean patient age was 66±11 years, with mean left ventricular ejection fraction of 48%±18%. Seventy-eight percent of the patients had structural heart disease.

During one year of follow up, multiple measures of quality-of-life showed significant and sustained improvement following ablation and pacing therapy. Also, left ventricular ejection increased significantly for patients with baseline left ventricular ejection fraction <45%. Metabolic exercise testing showed trends toward improved exercise tolerance; however, these did not achieve statistical significance. The one year overall survival was 85%, with 3% of patients experiencing sudden death.

In summary, this large, non-randomized, trial showed significant improvement in quality of life and left ventricular function following ablation and pacing therapy. Ablation and pacing therapy is a viable strategy for palliative management of patients with medically refractory, highly symptomatic atrial fibrillation.

Keywords: Atrial fibrillation; radiofrequency ablation; quality of life; left ventricular function

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.